^
Association details:
| Biomarker: | EML4-ALK fusion + ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1009P - Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
Published date:
09/05/2022
Excerpt:
We present an exploratory integrated analysis of the impact of EML4-ALK fusion and secondary ALK mutations on efficacy with brigatinib from two phase 2 studies in alectinib-refractory ALK+ NSCLC….Pts with a baseline detectable EML4-ALK fusion, compared with pts without detectable EML4-ALK fusion (n=54), had lower ORR (26.0% vs 37.0%), DoR (5.3 months vs not achieved [NA]), and PFS (3.5 vs 9.3 months).
